作者:Sunil Kher、Kirk Lake、Ila Sircar、Madhavi Pannala、Farid Bakir、James Zapf、Kui Xu、Shao-Hui Zhang、Juping Liu、Lisa Morera、Naoki Sakurai、Rick Jack、Jie-Fei Cheng
DOI:10.1016/j.bmcl.2007.06.017
日期:2007.8
Structure-activity relationship studies on a series of Boc-indole derivatives as LXR agonists are described. Compound 1 was identified as an LXR agonist through structure-based virtual screening followed by high-throughput gene profiling. Replacement of the indan linker portion in 1 with an open-chain linker resulted in compounds with similar or improved in vitro potency and cellular functional activity
描述了对一系列Boc-吲哚衍生物作为LXR激动剂的结构-活性关系的研究。通过基于结构的虚拟筛选,然后进行高通量基因分析,化合物1被确定为LXR激动剂。用开链接头替换1中的茚满接头部分,得到具有相似或改善的体外效能和细胞功能活性的化合物。吲哚部分的N-1位的Boc基可以被苯甲酰基取代。SAR研究导致在辅助因子募集测定中鉴定出EC8为12 nM的有效LXRbeta激动剂化合物8。